1. Home
  2. PSO vs PRAX Comparison

PSO vs PRAX Comparison

Compare PSO & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

HOLD

Current Price

$14.67

Market Cap

9.0B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$344.20

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSO
PRAX
Founded
1844
2015
Country
United Kingdom
United States
Employees
17062
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
9.0B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PSO
PRAX
Price
$14.67
$344.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
15
Target Price
N/A
$572.13
AVG Volume (30 Days)
1.0M
368.5K
Earning Date
02-27-2026
05-08-2026
Dividend Yield
2.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.26
N/A
Revenue Next Year
$4.54
$7,758.26
P/E Ratio
$14.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.02
$35.21
52 Week High
$16.62
$354.87

Technical Indicators

Market Signals
Indicator
PSO
PRAX
Relative Strength Index (RSI) 56.01 58.25
Support Level $14.28 $282.49
Resistance Level $14.88 $352.22
Average True Range (ATR) 0.21 20.88
MACD -0.07 0.42
Stochastic Oscillator 25.23 70.14

Price Performance

Historical Comparison
PSO
PRAX

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: